Table 1.
Demographic Features, Clinical Characteristics, Biochemical Parameters, Immunosuppressive Medication Use, and Echocardiographic Measurements of Study Patients at Study Time
| Patients (N=87) | |
|---|---|
| Age, y | 37.8±11.6 |
| Male sex, % | 43.7 |
| Cause of chronic renal failure, % | |
| Unknown origin | 52.9 |
| Others | 18.4 |
| Chronic glomerulonephritis | 12.6 |
| Reflux | 9.2 |
| Hypertension | 6.9 |
| Cadaveric transplantation, % | 23 |
| Previous renal replacement therapy time, mo | 36.5±40.7, median 21 (0–252) |
| Working fistula rate, % | 42.5 |
| Urea, mg/dL | 33.9±10.5 |
| Creatinine, mg/dL | 0.95±0.2 |
| MDRD, mL/min/m2 | 84.9±19.7 |
| Uric acid, mg/dL | 5.0±1.5 |
| Fasting blood glucose, mg/dL | 86.2±9.7 |
| Albumin, g/dL | 4.0±0.2 |
| Hemoglobin, g/dL | 13.4±1.8 |
| Total cholesterol, mg/dL | 193.0±32.7 |
| Triglycerides, mg/dL | 148.3±78.8 |
| LDL cholesterol, mg/dL | 113.4±26.2 |
| HDL cholesterol, mg/dL | 52.6±15.7 |
| Steroid, % | 98.9 |
| Tacrolimus, % | 79.3 |
| Cyclosporine, % | 13.8 |
| Mycophenolate mofetil, % | 34.5 |
| Mycophenolate sodium, % | 42.5 |
| Azathioprine, % | 12.1 |
| Rapamycin, % | 1.1 |
| Ejection fraction, % | 64.3±5.8 |
| Left ventricular mass index, g/m2 | 101.6±25.2 |
| Presence of diastolic dysfunction, % | 32.2 |
Abbreviations: HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; MDRD, Modification of Diet in Renal Disease.